Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix ( (GB:RENX) ) has provided an announcement.
Renalytix said Chief Executive James McCullough has increased his stake in the company by purchasing an additional 750 American Depositary Shares at an average price of $3.15 per ADS. Following the latest transaction, he now has an interest in 3,430,096 ordinary shares, representing 0.78% of the company’s issued share capital.
The move underscores management’s ongoing alignment with shareholders as Renalytix advances commercial deployment of its kidneyintelX.dkd prognostic test for diabetic kidney disease. With the product already FDA-approved, Medicare-reimbursed, and supported by real-world clinical data and guideline recommendations, the CEO’s further investment may be viewed as a signal of confidence in the company’s growth prospects and market positioning.
The most recent analyst rating on (GB:RENX) stock is a Sell with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early risk assessment in chronic diabetic kidney disease and is commercially available in the United States.
The company targets the large unmet need in diabetic kidney disease, which affects tens of millions of patients in the U.S. and U.K., and is deploying kidneyintelX.dkd across major physician groups and health systems. With over 15,000 patients tested and full Medicare reimbursement at $950 per reportable result, the test has generated real-world data showing higher rates of diagnosis, prognosis, and treatment, and is recommended in international chronic kidney disease guidelines.
Average Trading Volume: 572,116
Technical Sentiment Signal: Sell
Current Market Cap: £18.03M
For a thorough assessment of RENX stock, go to TipRanks’ Stock Analysis page.